This site is intended for healthcare professionals outside the US.

In in vitro/in vivo studies,

AFINITOR delivers a triple antitumor effect1-3

How AFINITOR inhibits angiogenesis1-3

  • AFINITOR limits the growth and proliferation of endothelial cells
  • AFINITOR prevents the release of VEGF and non-VEGF angiogenic growth factors from tumor cells

How AFINITOR inhibits growth and proliferation1,2

  • AFINITOR reduces the expression of proteins that regulate cell cycle progression and control cell proliferation

How AFINITOR inhibits metabolism1,2

  • AFINITOR reduces the activity of nutrient transporters to limit the uptake of nutrients involved in cell metabolism
Abbreviations:
MOA, mechanism of action; mTOR, mammalian target of rapamycin; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
References:
  1. AFINITOR [summary of product characteristics]. Novartis Pharma AG; May 2016.
  2. Yuan R, Kay A, Berg WJ, Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol. 2009;2:45.
  3. Dancey JE. Inhibitors of the mammalian target of rapamycin. Expert Opin Investig Drugs. 2005;14(3):313-328.